Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Pathogenesis and treatment of malnutrition in maintenance hemodialysis patients

Srinivasan Beddhu, MD
Monique E Cho, MD
Shweta Bansal, MD, FASN
Section Editor
Steve J Schwab, MD
Deputy Editor
Alice M Sheridan, MD


Measures of protein and energy stores such as body size [1-7], muscle mass [8,9], fat mass [8,9], serum albumin [10-12], and cholesterol [13] levels are strong predictors of survival in dialysis patients.

In 2009, the International Society of Renal Nutrition and Metabolism (ISRNM) recommended the term protein-energy wasting (PEW) syndrome to describe the loss of body protein mass and fuel reserves in dialysis patients [14]. The ISRNM developed objective criteria for the definition of PEW syndrome in dialysis and chronic kidney disease (CKD) patients [14].

This topic reviews the pathogenesis and treatment of PEW syndrome in hemodialysis patients.

The assessment of nutritional status and the effect of malnutrition on outcomes among hemodialysis patients are discussed elsewhere. (See "Assessment of nutritional status in hemodialysis patients" and "Patient survival and maintenance dialysis".)

The assessment, prevention, and treatment of malnutrition among patients on maintenance continuous peritoneal dialysis is discussed elsewhere. (See "Nutritional status and protein intake in peritoneal dialysis patients".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Thu Jan 12 00:00:00 GMT 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Abbott KC, Glanton CW, Trespalacios FC, et al. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study. Kidney Int 2004; 65:597.
  2. Beddhu S, Pappas LM, Ramkumar N, Samore M. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 2003; 14:2366.
  3. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81:543.
  4. Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010; 85:991.
  5. Port FK, Ashby VB, Dhingra RK, et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13:1061.
  6. Johansen KL, Young B, Kaysen GA, Chertow GM. Association of body size with outcomes among patients beginning dialysis. Am J Clin Nutr 2004; 80:324.
  7. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56:1136.
  8. Huang CX, Tighiouart H, Beddhu S, et al. Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Kidney Int 2010; 77:624.
  9. Kakiya R, Shoji T, Tsujimoto Y, et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70:549.
  10. Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.
  11. Kimmel PL, Chawla LS, Amarasinghe A, et al. Anthropometric measures, cytokines and survival in haemodialysis patients. Nephrol Dial Transplant 2003; 18:326.
  12. Kopple JD. Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. ASAIO J 1997; 43:246.
  13. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63:793.
  14. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391.
  15. Bossola M, Tazza L, Giungi S, Luciani G. Anorexia in hemodialysis patients: an update. Kidney Int 2006; 70:417.
  16. Kopple JD, Berg R, Houser H, et al. Nutritional status of patients with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease (MDRD) Study Group. Kidney Int Suppl 1989; 27:S184.
  17. Duenhas MR, Draibe SA, Avesani CM, et al. Influence of renal function on spontaneous dietary intake and on nutritional status of chronic renal insufficiency patients. Eur J Clin Nutr 2003; 57:1473.
  18. Wright M, Woodrow G, O'Brien S, et al. Cholecystokinin and leptin: their influence upon the eating behaviour and nutrient intake of dialysis patients. Nephrol Dial Transplant 2004; 19:133.
  19. Muscaritoli M, Molfino A, Chiappini MG, et al. Anorexia in hemodialysis patients: the possible role of des-acyl ghrelin. Am J Nephrol 2007; 27:360.
  20. Cheung W, Yu PX, Little BM, et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115:1659.
  21. Carrero JJ, Witasp A, Stenvinkel P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol Dial Transplant 2010; 25:901.
  22. Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80:299.
  23. Lindsay RM, Spanner E, Heidenheim RP, et al. Which comes first, Kt/V or PCR--chicken or egg? Kidney Int Suppl 1992; 38:S32.
  24. Kaysen GA, Greene T, Larive B, et al. The effect of frequent hemodialysis on nutrition and body composition: frequent Hemodialysis Network Trial. Kidney Int 2012; 82:90.
  25. Neyra R, Chen KY, Sun M, et al. Increased resting energy expenditure in patients with end-stage renal disease. JPEN J Parenter Enteral Nutr 2003; 27:36.
  26. Beddhu S, Wei G, Marcus RL, et al. Light-intensity physical activities and mortality in the United States general population and CKD subpopulation. Clin J Am Soc Nephrol 2015; 10:1145.
  27. Anderton N, Giri A, Wei G, et al. Sedentary Behavior in Individuals With Diabetic Chronic Kidney Disease and Maintenance Hemodialysis. J Ren Nutr 2015; 25:364.
  28. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17:1453.
  29. Thijssen S, Wong MM, Usvyat LA, et al. Nutritional Competence and Resilience among Hemodialysis Patients in the Setting of Dialysis Initiation and Hospitalization. Clin J Am Soc Nephrol 2015; 10:1593.
  30. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335:1897.
  31. Kaysen GA, Dubin JA, Müller HG, et al. Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in hemodialysis patients. Kidney Int 2003; 63:315.
  32. Beddhu S, Filipowicz R, Chen X, et al. Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study. BMC Nephrol 2015; 16:87.
  33. Ramkumar N, Cheung AK, Pappas LM, et al. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr 2004; 14:201.
  34. Axelsson J, Heimbürger O, Lindholm B, Stenvinkel P. Adipose tissue and its relation to inflammation: the role of adipokines. J Ren Nutr 2005; 15:131.
  35. Pupim LB, Flakoll PJ, Majchrzak KM, et al. Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. Kidney Int 2005; 68:1857.
  36. Siew ED, Pupim LB, Majchrzak KM, et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71:146.
  37. Wang X, Hu Z, Hu J, et al. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006; 147:4160.
  38. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271:665.
  39. Bailey JL, Wang X, England BK, et al. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 1996; 97:1447.
  40. Reaich D, Channon SM, Scrimgeour CM, et al. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 1993; 265:E230.
  41. Graham KA, Reaich D, Channon SM, et al. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 1997; 8:632.
  42. Stein A, Moorhouse J, Iles-Smith H, et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997; 52:1089.
  43. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20:2075.
  44. Kaysen GA, Greene T, Daugirdas JT, et al. Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. Am J Kidney Dis 2003; 42:1200.
  45. Ikizler TA, Pupim LB, Brouillette JR, et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. Am J Physiol Endocrinol Metab 2002; 282:E107.
  46. Ikizler TA. Effects of hemodialysis on protein metabolism. J Ren Nutr 2005; 15:39.
  47. Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int 1981; 19:593.
  48. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int 1994; 46:830.
  49. Sherman RA, Cody RP, Rogers ME, Solanchick JC. Interdialytic weight gain and nutritional parameters in chronic hemodialysis patients. Am J Kidney Dis 1995; 25:579.
  50. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.
  51. Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant 2007; 22 Suppl 2:ii5.
  52. Mitch WE, Remuzzi G. Diets for patients with chronic kidney disease, still worth prescribing. J Am Soc Nephrol 2004; 15:234.
  53. Marzocco S, Dal Piaz F, Di Micco L, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif 2013; 35:196.
  54. Streja E, Lau WL, Goldstein L, et al. Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney Int Suppl (2011) 2013; 3:462.
  55. Cohen SD, Norris L, Acquaviva K, et al. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol 2007; 2:1332.
  56. Martinson M, Ikizler TA, Morrell G, et al. Associations of body size and body composition with functional ability and quality of life in hemodialysis patients. Clin J Am Soc Nephrol 2014; 9:1082.
  57. van den Ham EC, Kooman JP, Schols AM, et al. The functional, metabolic, and anabolic responses to exercise training in renal transplant and hemodialysis patients. Transplantation 2007; 83:1059.
  58. Kopple JD, Wang H, Casaburi R, et al. Exercise in maintenance hemodialysis patients induces transcriptional changes in genes favoring anabolic muscle. J Am Soc Nephrol 2007; 18:2975.
  59. Castaneda C, Gordon PL, Parker RC, et al. Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 2004; 43:607.
  60. Johannsson G, Bengtsson BA, Ahlmén J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999; 33:709.
  61. Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18:2161.
  62. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.
  63. Rocco MV, Dwyer JT, Larive B, et al. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2321.
  64. FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363:2287.
  65. Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18:2583.
  66. Lacson E Jr, Wang W, Zebrowski B, et al. Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report. Am J Kidney Dis 2012; 60:591.
  67. Weiner DE, Tighiouart H, Ladik V, et al. Oral intradialytic nutritional supplement use and mortality in hemodialysis patients. Am J Kidney Dis 2014; 63:276.
  68. Caglar K, Fedje L, Dimmitt R, et al. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 2002; 62:1054.
  69. Eustace JA, Coresh J, Kutchey C, et al. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int 2000; 57:2527.
  70. Hiroshige K, Sonta T, Suda T, et al. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 2001; 16:1856.
  71. Leon JB, Albert JM, Gilchrist G, et al. Improving albumin levels among hemodialysis patients: a community-based randomized controlled trial. Am J Kidney Dis 2006; 48:28.
  72. Kalantar-Zadeh K, Braglia A, Chow J, et al. An anti-inflammatory and antioxidant nutritional supplement for hypoalbuminemic hemodialysis patients: a pilot/feasibility study. J Ren Nutr 2005; 15:318.
  73. Bronich L, Te T, Shetye K, et al. Successful treatment of hypoalbuminemic hemodialysis patients with a modified regimen of oral essential amino acids. J Ren Nutr 2001; 11:194.
  74. Oğuz Y, Bulucu F, Vural A. Oral and parenteral essential amino acid therapy in malnourished hemodialysis patients. Nephron 2001; 89:224.
  75. Moretti HD, Johnson AM, Keeling-Hathaway TJ. Effects of protein supplementation in chronic hemodialysis and peritoneal dialysis patients. J Ren Nutr 2009; 19:298.
  76. Fouque D, McKenzie J, de Mutsert R, et al. Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant 2008; 23:2902.
  77. Pupim LB, Majchrzak KM, Flakoll PJ, Ikizler TA. Intradialytic oral nutrition improves protein homeostasis in chronic hemodialysis patients with deranged nutritional status. J Am Soc Nephrol 2006; 17:3149.
  78. Wolfson M. Use of intradialytic parenteral nutrition in hemodialysis patients. Am J Kidney Dis 1994; 23:856.
  79. Kopple JD. Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support. Am J Kidney Dis 1999; 33:180.
  80. Abras E, Walser M. Nitrogen utilization in uremic patients fed by continuous nasogastric infusion. Kidney Int 1982; 22:392.
  81. Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46:371.
  82. Pupim LB, Flakoll PJ, Brouillette JR, et al. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest 2002; 110:483.
  83. Foulks CJ. An evidence-based evaluation of intradialytic parenteral nutrition. Am J Kidney Dis 1999; 33:186.
  84. Capelli JP, Kushner H, Camiscioli TC, et al. Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care. Am J Kidney Dis 1994; 23:808.
  85. Wolfson M, Jones MR, Kopple JD. Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 1982; 21:500.
  86. McCann L, Feldman C, Hornberger J, et al. Effect of intradialytic parenteral nutrition on delivered Kt/V. Am J Kidney Dis 1999; 33:1131.
  87. Ziegler TR, Lazarus JM, Young LS, et al. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 1991; 2:1130.
  88. Ikizler TA, Wingard RL, Breyer JA, et al. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 1994; 46:1178.
  89. Ikizler TA, Wingard RL, Hakim RM. Interventions to treat malnutrition in dialysis patients: the role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Am J Kidney Dis 1995; 26:256.
  90. Fouque D, Peng SC, Shamir E, Kopple JD. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int 2000; 57:646.
  91. Hansen TB, Gram J, Jensen PB, et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000; 53:99.
  92. Garibotto G, Barreca A, Sofia A, et al. Effects of growth hormone on leptin metabolism and energy expenditure in hemodialysis patients with protein-calorie malnutrition. J Am Soc Nephrol 2000; 11:2106.
  93. Garibotto G, Barreca A, Russo R, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99:97.
  94. Iglesias P, Díez JJ, Fernández-Reyes MJ, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis 1998; 32:454.
  95. Kotzmann H, Schmidt A, Lercher P, et al. One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients. Nephron Clin Pract 2003; 93:C75.
  96. Kopple JD, Cheung AK, Christiansen JS, et al. OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant 2011; 26:4095.
  97. Gascón A, Belvis JJ, Berisa F, et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9:67.
  98. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275.
  99. Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002; 58:38.
  100. Atkin-Thor E, Goddard BW, O'Nion J, et al. Hypogeusia and zinc depletion in chronic dialysis patients. Am J Clin Nutr 1978; 31:1948.